Logroscino G, Hesdorffer DC, Cascino G, Hauser WA, Coeytaux A, Galobardes B, Morabia A, Jallon P (2005) Mortality after a first episode of status epilepticus in the United States and Europe. https://doi.org/10.1111/j.1528-1167.2005.00409.x. Epilepsia 46 Suppl 11:46 – 8

Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH (2015) A definition and classification of status epilepticus: report of the ILAE Task Force on classification of Status Epilepticus. Epilepsia 56:1515–1523

Article  PubMed  Google Scholar 

Leitinger M, Trinka E, Giovannini G, Zimmermann G, Florea C, Rohracher A, Kalss G, Neuray C, Kreidenhuber R, Höfler J et al (2019) Epidemiology of status epilepticus in adults: a population-based study on incidence, causes and outcomes. Epilepsia 60:53–62

Article  PubMed  Google Scholar 

Holtkamp M, Othman J, Buchheim K, Meierkord H (2005) Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 76(4):534–539. https://doi.org/10.1136/jnnp.2004.041947

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marawar R, Basha M, Mahulikar A, Desai A, Suchdev K, Shah A (2018) Updates in Refractory Status Epilepticus. Crit Care Res Pract 9768949. https://doi.org/10.1155/2018/9768949

Novy J, Logroscino G, Rossetti AO (2010) Refractory status epilepticus: a prospective observational study. Epilepsia 51(2):251–256. https://doi.org/10.1111/j.1528-1167.2009.02323.x

Article  PubMed  Google Scholar 

Walker MC (2018) Pathophysiology of status epilepticus Neurosci Lett 22;667:84–91. https://doi.org/10.1016/j.neulet.2016.12.044

Naylor DE, Liu H, Wasterlain CG (2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25(34):7724–7733. https://doi.org/10.1523/JNEUROSCI.4944-04.2005

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niquet J, Baldwin R, Suchomelova L, Lumley L, Naylor D, Eavey R, Wasterlain CG (2016) Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment. Ann N Y Acad Sci 1378(1):166–173. https://doi.org/10.1111/nyas.13147

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wasterlain CG, Liu H, Naylor DE, Thompson KW, Suchomelova L, Niquet J, Mazarati AM, Baldwin RA (2009) Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited. Epilepsia 50 Suppl. https://doi.org/10.1111/j.1528-1167.2009.02375.x. 12:16 – 8

Article  Google Scholar 

Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS, Dash A (2018) Perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand 137(4):378–391. https://doi.org/10.1111/ane.12879

Article  CAS  PubMed  Google Scholar 

Perez DQ, Espiritu AI, Jamora RDG (2022) Perampanel in achieving status epilepticus cessation: a systematic review. Epilepsy Behav 128:108583. https://doi.org/10.1016/j.yebeh.2022.108583

Article  PubMed  Google Scholar 

Beretta S, Padovano G, Stabile A, Coppo A, Bogliun G, Avalli L, Ferrarese C (2018) Efficacy and safety of perampanel oral loading in postanoxic super-refractory status epilepticus: a pilot study. Epilepsia 59:243–248

Article  CAS  PubMed  Google Scholar 

Redecker J, Wittstock M, Benecke R, Rösche J (2015) Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav 45:176–179

Article  PubMed  Google Scholar 

Rohracher A, Kalss G, Neuray C, Höfler J, Dobesberger J, Kuchukhidze G, Kreidenhuber R, Florea C, Thomschewski A, Novak HF et al (2018) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients. Epilepsia 59:234–242

Article  CAS  PubMed  Google Scholar 

Brigo F, Lattanzi S, Rohracher A, Russo E, Meletti S, Grillo E, Trinka E (2018) Perampanel in the treatment of status epilepticus: a systematic review of the literature. Epilepsy Behav 86:179–186

Article  PubMed  Google Scholar 

Villanueva V, D’Souza W, Goji H, Kim DW, Liguori C, McMurray R, Najm I, Santamarina E, Steinhoff BJ, Vlasov P, Wu T, Trinka E, PERMIT pooled analysis participants (2022) PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. J Neurol 269(4):1957–1977.https://doi.org/10.1007/s00415-021-10751-y

Article  PubMed  Google Scholar 

Nilo A, Vogrig A, Belluzzo M, Lettieri C, Verriello L, Valente M, Pauletto G (2023) Efficacy of Perampanel in Refractory and Super-refractory Status Epilepticus with suspected inflammatory etiology: a Case Series. Pharmaceuticals (Basel) 17(1):24. https://doi.org/10.3390/ph17010028

Article  CAS  Google Scholar 

Coppola A, Zarabla A, Maialetti A, Villani V, Koudriavtseva T, Russo E, Nozzolillo A, Sueri C, Belcastro V, Balestrini S, Ferlazzo E, Giannarelli D, Bilo L, Maschio M (2020) Perampanel confirms to be effective and well-tolerated as an Add-On treatment in patients with brain tumor-related Epilepsy (PERADET Study). Front Neurol 25:11592. https://doi.org/10.3389/fneur.2020.00592eCollection 2020

Article  Google Scholar 

Pascarella A, Manzo L, Gasparini S, Marsico O, Abelardo D, Torino C, Cianci V, Iudice A, Bisulli F, Bonanni P, Caggia E, D’Aniello A, Di Bonaventura C, DiFrancesco JC, Domina E, Dono F, Gambardella A, Fortunato F, Marini C, Marrelli A, Matricardi S, Morano A, Paladin F, Renna R, Piccioli M, Striano P, Ascoli M, La Neve A, Le Piane E, Orsini A, Di Gennaro G, Aguglia U, Ferlazzo E (2024) PEROC Study Group. Perampanel in post-stroke epilepsy: clinical practice data from the PERampanel as only concomitant antiseizure medication (PEROC) study. J Neurol Sci 15:462:123106. https://doi.org/10.1016/j.jns.2024.123106Epub 2024 Jun 21

Article  CAS  Google Scholar 

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A (2013) Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 54(1):126–134. https://doi.org/10.1111/j.1528-1167.2012.03648.x

Article  CAS  PubMed  Google Scholar